Written by Dr Caroline Daly
This post describes themes of suicide, self-harm and self-harm methods. These may be distressing or triggering to read. If you are particularly affected by this content, please avail of the supports available to you, namely your GP, local emergency services or allied support services such as the Samaritans (Freephone 116 123) or Pieta (1800 247 247) or visit our Finding Help and Supports page.
"Over one half of people bought the tablets for the overdose and almost one third planned the overdose for less than an hour before overdosing" (Simkin et al., 2012).
These and similar insights from people who overdosed on non-opioid analgesics highlight the fundamental roles of availability and impulsivity in these acts.
Paracetamol is a trusted, effective and safe drug when used correctly. But it is also “the most widely available drug that’s legal with a fair chance of achieving the ultimate goal”. This is where the issue lies, how do we balance public access with individual safety?
Non opioid analgesics remain the drugs most often taken in hospital-presenting self-harm and are commonly implicated in fatal poisonings here in Ireland (Joyce et al., 2026; Kelleher et al., 2025). Many of the overdoses recorded by the National Self-Harm Registry Ireland involve a potentially acute toxic dosage, potentially explaining why the risk of liver transplant following overdose in Ireland is 6-times the European average (Gulmez et al., 2015). Compounding these concerns the rates of these overdoses peak and are increasing for young people under 25 years (Daly et al., 2021).
To address the devastating outcomes of non-opioid analgesic overdose, restrictions on their sale have been in place in Ireland since 2001 (Department of Health, 2001). Restricting access to means used in suicidal acts is an effective upstream public health measure, particularly when a method, like these overdoses, is common and accessible. As most suicidal acts are highly impulsive means restriction works by reducing physical access and allowing time for the crisis to pass or lessen (Hawton et al., 2024). The restrictive measures imposed on paracetamol sales in Ireland did impact the toxicity of overdoses however the frequency and severity of these acts raises many questions (Donohoe et al., 2006).
We must ask is the existing legislation being adhered to and secondly could additional restrictions be considered? Emerging evidence from the Preventing Paracetamol-Related Intentional Drug Overdose Working Group in Ireland indicates that adherence to existing legislation is not universal highlighting compliance issues (Austin et al., 2024), building on previous research highlighting this issue (Ni Mhaolain et al., 2009). Findings from the Working Group attribute adherence issues to limited understanding around the rationale underpinning the restrictions, insufficient staff training and a lack of penalties for retailers who do not adhere to requirements. In 2023, the Department of Health launched a campaign to address issues with and improve adherence, with the outcomes to be published soon.
Two measures from the international literature warrant consideration. A European multi-centre study found that countries where paracetamol was not available in retail outlets had fewer paracetamol-related enquiries, noting restrictive site of sale measures as advisable (Morthorst et al., 2018). Furthermore, in Denmark an age restriction in sales of over-the-counter non-opioid analgesics to those 18 and over resulted in a 17% reduction in hospital admissions following overdose (Morthorst et al., 2020). It is time that such interventions are explored, both of which are not about prohibition but safer access. Whilst they will likely result in inconvenience to consumers, many public health measures prioritise safety over convenience. Particularly the proposed age restriction is warranted given the pervasive issue of overdose among young people and the existence of similar effective measures which ensure the safe sale of alcohol, tobacco, vapes and glue.
Importantly, means restriction is one component of a broader strategy to reduce overdose which should also encompass safety planning, safe medication disposal and storage and broader supports and treatment for people in crisis. Whilst tighter means restriction is not a standalone solution, given the outcomes associated with these overdoses they are measures that warrant timely and serious consideration.
Simkin S, Hawton K, Kapur N, Gunnell N. (2012) What can be done to reduce mortality from paracetamol overdoses? A patient interview study. QJM: An International Journal of Medicine 105(1):41-51.
Joyce, M., Chakraborty, S., McGuiggan, J.C., Hursztyn, P., Arensman, E., Griffin, E., Corcoran, P. (2026). National Self-Harm Registry Ireland Annual Report 2025. Cork: National Suicide Research Foundation.
Kelleher, C., Riordan, F. and Gopalakrishnan, A. (2025) Drug poisoning deaths in Ireland in 2022: Data from the National Drug-Related Deaths Index (NDRDI). HRB StatLink Series 28. Dublin: Health Research Board.
Gulmez, S.E., Larrey, D., Pageaux, G.P., Bernuau, J., Bissoli, F., Horsmans, Y., Thorburn, D., McCormick, P.A., Stricker, B.H.C. et al. (2015) Liver transplant associated with paracetamol overdose: results from the seven-country SALT study, British Journal of Clinical Pharmacology, 80(3), pp. 599-606.
Daly, C., Griffin, E., McMahon, E., Corcoran, P., Webb, R.T., Ashcroft, D.M. and Arensman, E. (2021) Paracetamol-related intentional drug overdose among young people: a national registry study of characteristics, incidence and trends, 2007–2018, Social Psychiatry and Psychiatric Epidemiology, 56(5), pp. 773–781.
Department of Health and Children (2001) Medicinal Products (Control of Paracetamol) Regulations, 2001 (S.I. No. 150/2001). Dublin: Stationery Office. Available at: https://www.irishstatutebook.ie/eli/2001/si/150/made/en/print.
Hawton, K., Knipe, D. and Pirkis, J. (2024) ‘Restriction of access to means used for suicide’, The Lancet Public Health, 9(10), pp. e796-e801.
Donohoe, E., Walsh, N. and Tracey, J.A. (2006) ‘Pack-size legislation reduces severity of paracetamol overdoses in Ireland’, Irish Journal of Medical Science, 175(3), pp. 40–42.
Austin, C., O'Driscoll, M. and O'Neill, A. (2024) Safe sales of paracetamol in a pharmacy setting: Updates from the Preventing Paracetamol-Related Intentional Drug Overdose Working Group. Webinar, Irish Institute of Pharmacy, 24 January 2024. Available at: https://iiop.ie/content/safe-sales-paracetamol-pharmacy-setting-updates-preventing-paracetamol-related-intentional.
Ni Mhaolain AM, Davoren M, Kelly BD, Breen E, Casey P. (2009) Paracetamol availability in pharmacy and non-pharmacy outlets in Dublin, Ireland. Ir J Med Sci. 178(1):79-82.
Morthorst B, Erlangsen A, Nordentoft M, Hawton K, Groth Hoeberg LC, Dalhoff K. (2018) Availability of Paracetamol Sold Over the Counter in Europe: A Descriptive Cross-Sectional International Survey of Pack Size Restriction. Basic Clin Pharmacol Toxicol 122, 643-649.
Morthorst, B.R., Erlangsen, A., Chaine, M., Eriksson, F., Hawton, K., Dalhoff, K. and Nordentoft, M. (2020) ‘Restriction of non-opioid analgesics sold over-the-counter in Denmark: A national study of impact on poisonings’, Journal of Affective Disorders, 268, pp. 61-68.
